[Ip-health] MSF responds to second Wikileaks release of Trans-Pacific Partnership text

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Thu Oct 16 04:29:11 PDT 2014

MSF responds to second Wikileaks release of Trans-Pacific Partnership text
16 October, 2014

Today Wikileaks published a revised copy of the intellectual property
chapter from the secret Trans-Pacific Partnership (TPP) negotiations:
https://wikileaks.org/tpp-ip2/. The leaked document -- dated May 2014 –
also discloses countries’ current negotiating positions. Wikileaks had
released an earlier version of the IP chapter in November 2013.

A preliminary review of the text confirms MSF’s serious concerns about the
Agreement’s public health impact remain valid:  some of the most damaging
intellectual property provisions remain in the text.  Adopting the text in
its current form will negatively affect affordable access to medicines and
the health of millions of people across the Asia-Pacific region.

Statement by Judit Rius Sanjuan, U.S. Manager and Legal Policy Advisor, MSF
Access Campaign:

“Although we’d much prefer if negotiating countries themselves abandoned
the extreme secrecy that has characterized these negotiations, MSF welcomes
the leak of the revised negotiating text as a means to facilitate an open,
transparent discussion about the health impacts of this agreement on MSF
medical operations and millions of patients in TPP countries and beyond.

“The leaked text reveals that most of the more problematic provisions are
being pushed by the United States and Japan, while still being opposed by
the majority of the rest of negotiating countries. While the Australian
government continues to oppose many of the most problematic provisions, we
are concerned about Australian support for the U.S. government’s push to
mandate rules that facilitate secondary and abusive patenting by
pharmaceutical companies, which blocks more affordable generic competition.
As countries prepare for TPP negotiations in Australia starting October 19,
we once again urge all countries to reject harmful intellectual property
provisions that will restrict access to medicines.”

Some of the most harmful provisions remaining in the text would:
- Limit countries’ ability to exercise rights confirmed in the 2001 Doha
Declaration, by restricting those rights to a specific list of diseases and
- Limit the capacity that countries have to restrict secondary patenting
and abusive patenting by requiring patents on “new uses or methods of using
a known product.”
- Restrict countries’ ability to include important public health
flexibilities in their own national laws, for example India’s Section 3(d)
patent law which requires evidence of “enhanced efficacy” before additional
patents can be granted on existing products.
- Restrict countries’ ability to use to the full the public health
flexibilities recognized in the TRIPS agreement, including compulsory
licenses and patent exceptions.
- Mandate that countries include TRIPS-plus measures in their national
laws, including patent linkage, patent term extensions and new monopolies
based on clinical data exclusivity, including for biological vaccines and
medicines, which have never before been included in a US-led trade

More info: http://www.msfaccess.org/tpp/

Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: @joanna_keenan


More information about the Ip-health mailing list